Regular ArticleGlycoaminoglycan (GAG) deficiency in protective barrier as an underlying, primary cause of ulcerative colitis, Crohn's disease interstitial cystitis and possibly Reiter's syndrome
References (32)
- et al.
Articular cartilage pharmacology. I. In vitro studies on glucosamine and non steroidal antiinflammatory drugs
Pharmacol Res Commun
(1978) The neglect of glucosamine as a treatment for osteoarthritis – a personal perspective
Med Hypotheses
(1994)- et al.
Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis
J Urol
(1996) - et al.
Spondylarthropathy and gut inflammation: immunopathogenetic mechanisms
Int J Tiss Reac
(1992) - et al.
Effect of anti-inflammatory agents on L-glutamine-D-fructose-6-phosphate transaminase
Arzneim-Forsh Drug Res
(1976) - et al.
Effects of protamine, heparanase and hyaluronidase on endothelial permeability and surface change
J Appl Physiol
(1987) - et al.
Disruption of sulphated glycosaminoglycans in intestinal inflammation
Lancet
(1993) - et al.
Comparative histochemistry of gastrointestinal mucosubstances
Am J Anar
(1976) - et al.
The diagnostic value of mucosubstances in rectal biopsies from patients with ulcerative colitis and Crohn's Disease
Gut
(1970) - et al.
Glucosamine synthetase activity of the colonic mucosa in ulcerative colitis and Crohn's disease
Gut
(1977)
Sulphated polysaccharide inhibition of aortic uptake of low density lipoproteins
Artery
Glycosaminoglycans and coronary heart disease
Glycosaminoglycans and Proteoglycans in Physiological and Pathological Processes of Body Systems
In vitro and ex vivo regulation of vascular smooth muscle cell growth and phenotypic modulation by sulphated polysaccharides
Artery
Cited by (23)
Polysaccharides from natural resources exhibit great potential in the treatment of ulcerative colitis: A review
2021, Carbohydrate PolymersCitation Excerpt :The lack of the GAG defense barrier is one of the causes of UC, which can lead to toxin infiltration, a local inflammatory response, and many pathological and immune changes. A side effect of nonsteroidal anti-inflammatory drugs on the gastrointestinal tract is the inhibition of glucosamine synthetase, which leads to a decrease in the GAG layer (Russell, 1999). Because of their hydrophilicity, GAGs form a large volume of gel to help maintain tissue expansion and the structure of the intestinal wall and prevent the intestinal epithelial barrier from being damaged.
Glyconutrients: The State of the Science and the Impact of Glycomics
2006, Explore: The Journal of Science and HealingCitation Excerpt :Much of the literature on the clinical use of glyconutrients, such as illustrated by the three studies above, has been inconclusive and preliminary. A number of case reports and small pilot studies for conditions such as Tay-Sachs disease,16 chronic fatigue syndrome and fibromyalgia,17 attention deficit hyperactivity disorder,18 diabetes,19 autoimmune disease,20 inflammatory bowel disease and interstitial cystitis,21 and others have been reported. These provide intriguing leads for the future.
Glycosaminoglycan profile in bladder and urethra of castrated rats treated with estrogen, progestogen, and raloxifene
2003, American Journal of Obstetrics and GynecologyOptimising the management of bladder pain syndrome
2021, Journal of Clinical UrologyPrevention of sinonasal inflammation by a synthetic glycosaminoglycan
2017, International Forum of Allergy and Rhinology